E
Enli Liu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 63
Citations - 10901
Enli Liu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Stem cell & Antigen. The author has an hindex of 29, co-authored 62 publications receiving 8804 citations. Previous affiliations of Enli Liu include Center for Cell and Gene Therapy & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi,Siok-Keen Tey,Gianpietro Dotti,Yuriko Fujita,Alana A. Kennedy-Nasser,Caridad Martinez,Karin Straathof,Enli Liu,April G. Durett,Bambi Grilley,Hao Liu,Conrad Russell Y. Cruz,Barbara Savoldo,Adrian P. Gee,John Schindler,Robert A. Krance,Helen E. Heslop,David M. Spencer,Cliona M. Rooney,Malcolm K. Brenner +19 more
TL;DR: The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal ArticleDOI
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis,Chrystal U. Louis,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti,Martin Pule,Eric Yvon,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Oumar Diouf,Oumar Diouf,Enli Liu,Hao Liu,Meng Fen Wu,Adrian P. Gee,Zhuyong Mei,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +23 more
TL;DR: It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.
Journal ArticleDOI
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Barbara Savoldo,Carlos A. Ramos,Carlos A. Ramos,Enli Liu,Martha P. Mims,Michael J. Keating,George Carrum,George Carrum,Rammurti T. Kamble,Rammurti T. Kamble,Catherine M. Bollard,Catherine M. Bollard,Adrian P. Gee,Zhuyong Mei,Hao Liu,Bambi Grilley,Bambi Grilley,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner,Gianpietro Dotti +21 more
TL;DR: The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.